XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Share-Based Payments (Tables)
 9 Months Ended
Jan. 31, 2022
Share-based Payment Arrangement [Abstract]  
Summary of allocation of share based compensation expense
Stock-based compensation expense was recognized as follows (table in thousands):
 
Three Months Ended
January 31,		Nine Months Ended
January 31,
 2022202120222021
General and administrative$223 $149 $442 $206 
Sales and marketing53 51 149 148 
Research and development3 7 17 16 
Cost of oncology services31 25 116 67 
Total stock-based compensation expense$310 $232 $724 $437 
Summary of valuation assumptions for stock options
Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2022 and 2021 were as follows:
 
Three Months Ended
January 31,		Nine Months Ended
January 31,
 2022202120222021
Expected term in years
6
3
6
3-6
Risk-free interest rates
1.11%-1.20%
0.12%
0.82%-1.20%
0.12%-0.39%
Volatility
64.37%-64.62%
74.98%
64.37%-66.21%
72.64%-74.98%
Dividend yield—%—%—%—%
Summary of stock option activity
The Company’s stock options activity for the nine months ended January 31, 2022 was as follows:
 
Directors
and
Employees		Non-
Employees		TotalWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding, April 30, 20211,618,231 35,415 1,653,646 $3.96 5.42$11,384,000 
Granted155,552 10,500 166,052 9.44 9.59
Exercised(103,875)— (103,875)2.24 
Forfeited(20,500)— (20,500)7.14   
Canceled(8,875)— (8,875)4.83 
Expired— (5,000)(5,000)9.60   
Outstanding, January 31, 20221,640,533 40,915 1,681,448 4.54 5.22$6,611,000 
Vested and expected to vest as of January 31, 20221,640,533 40,915 1,681,448 4.54 5.22$6,611,000 
Exercisable as of January 31, 20221,288,349 4,584 1,292,933 3.77 4.31$6,057,000